RAS antibody (AA 1-186)

Catalog No. ABIN5776161

This Mouse Monoclonal antibody specifically detects RAS in WB, IF, ICC and ELISA. It exhibits reactivity toward Human.

Quick Overview for RAS antibody (AA 1-186) (ABIN5776161)

Target: RAS

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This RAS antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Immunocytochemistry (ICC), ELISA

Clone: AT2F8

Product Details anti-RAS Antibody

Binding Specificity: AA 1-186

Purpose: Human Ras antibody

Purification: Purified

Immunogen: Recombinant human KRAS (1-186aa) purified from E. coli

Isotype: IgG2b kappa

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: Phosphate-Buffered Saline ( pH 7.4) with 0.02 % Sodium Azide, 10 % glycerol

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

Target Details for RAS

Target: RAS

Alternative Name: Ras

Background: All RAS protein family members belong to a class of protein called small GTPase, and are involved cellular signal transduction. RAS is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. Mutations in RAS genes can lead to the production of permanently activated RAS proteins. This can cause unintended and overactive signaling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive RAS signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRas, KRas, NRas) are the most common oncogenes in human cancer, mutations that permanently activate RAS are found in 20 % to 25 % of all human tumors and up to 90 % in certain types of cancer. RAS inhibitors are being studied as a treatment for cancer, and other diseases with RAS overexpression.

NCBI Accession: NP_203524